These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28540417)

  • 21. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
    Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
    Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations.
    Thorwarth D; Eschmann SM; Paulsen F; Alber M
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):515-21. PubMed ID: 17398015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer.
    Eschmann SM; Paulsen F; Bedeshem C; Machulla HJ; Hehr T; Bamberg M; Bares R
    Radiother Oncol; 2007 Jun; 83(3):406-10. PubMed ID: 17543402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
    Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
    PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
    Zips D; Zöphel K; Abolmaali N; Perrin R; Abramyuk A; Haase R; Appold S; Steinbach J; Kotzerke J; Baumann M
    Radiother Oncol; 2012 Oct; 105(1):21-8. PubMed ID: 23022173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
    Lee N; Schoder H; Beattie B; Lanning R; Riaz N; McBride S; Katabi N; Li D; Yarusi B; Chan S; Mitrani L; Zhang Z; Pfister DG; Sherman E; Baxi S; Boyle J; Morris LG; Ganly I; Wong R; Humm J
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):9-17. PubMed ID: 27511842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
    Kazmierska J; Cholewinski W; Piotrowski T; Sowinska A; Bak B; Cegła P; Malicki J
    Br J Radiol; 2020 Feb; 93(1106):20180781. PubMed ID: 31860336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
    Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
    Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.
    Wiedenmann NE; Bucher S; Hentschel M; Mix M; Vach W; Bittner MI; Nestle U; Pfeiffer J; Weber WA; Grosu AL
    Radiother Oncol; 2015 Oct; 117(1):113-7. PubMed ID: 26432067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
    Fatema CN; Zhao S; Zhao Y; Yu W; Nishijima K; Yasuda K; Kitagawa Y; Tamaki N; Kuge Y
    BMC Cancer; 2014 Sep; 14():692. PubMed ID: 25245041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular hypoxia measured by
    Asano A; Ueda S; Kuji I; Yamane T; Takeuchi H; Hirokawa E; Sugitani I; Shimada H; Hasebe T; Osaki A; Saeki T
    Breast Cancer Res; 2018 Jul; 20(1):78. PubMed ID: 30053906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.
    Boeke S; Winter RM; Leibfarth S; Krueger MA; Bowden G; Cotton J; Pichler BJ; Zips D; Thorwarth D
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3084-3096. PubMed ID: 37148296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.